Noxopharm Limited

ASX:NOX Stock Report

Market Cap: AU$26.3m

Noxopharm Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Gisela Mautner

Chief executive officer

AU$500.6k

Total compensation

CEO salary percentage94.3%
CEO tenure2.9yrs
CEO ownershipn/a
Management average tenure4yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Aug 24
Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Jul 22
We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Nov 10
We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Jun 04
Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17
Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04
These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

CEO Compensation Analysis

How has Gisela Mautner's remuneration changed compared to Noxopharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$501kAU$472k

-AU$4m

Mar 31 2024n/an/a

-AU$8m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$14m

Jun 30 2023AU$492kAU$410k

-AU$15m

Mar 31 2023n/an/a

-AU$15m

Dec 31 2022n/an/a

-AU$15m

Sep 30 2022n/an/a

-AU$17m

Jun 30 2022AU$1mAU$201k

-AU$19m

Compensation vs Market: Gisela's total compensation ($USD314.54K) is about average for companies of similar size in the Australian market ($USD285.36K).

Compensation vs Earnings: Gisela's compensation has increased whilst the company is unprofitable.

CEO

Gisela Mautner

2.9yrs

Tenure

AU$500,623

Compensation

Dr. Gisela Mautner is Non-Executive Director of Nyrada Inc. from August 1, 2022. She serves as Director at Noxopharm Limited. She served as Chief Medical Officer at Noxopharm Limited since October 2019 unt...

Leadership Team

NamePositionTenureCompensationOwnership
Gisela Mautner
CEO, Executive MD & Director2.9yrsAU$500.62kno data
Shawn Van Boheemen
Chief Financial Officer5.8yrsno datano data
Jeanette Bell
Chief Operating Officer5yrsno datano data
John Wilkinson
Chief Scientific Officer of Oncology3yrsno datano data
Olivier Laczka
Chief Scientific Officer of Inflammation3yrsno datano data
David Franks
Company Secretary8yrsAU$16.49kno data

4.0yrs

Average Tenure

Experienced Management: NOX's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gisela Mautner
CEO, Executive MD & Directorno dataAU$500.62kno data
Frederick Bart
Non-Executive Chairman4.7yrsAU$45.00k2.57%
A$ 675.7k
Peter Marks
Non-Executive Deputy Chairman8.8yrsAU$60.00k0.31%
A$ 81.0k
Boris Patkin
Non-Executive Director4.8yrsAU$45.00k0.22%
A$ 56.7k

4.8yrs

Average Tenure

70yo

Average Age

Experienced Board: NOX's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 19:12
End of Day Share Price 2025/01/22 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Noxopharm Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution